Steady-State Pharmacokinetics of Oral Voriconazole and Its Primary Metabolite, <i>N</i> -Oxide Voriconazole, Pre- and Post-Autologous Peripheral Stem Cell Transplantation

Abstract

Voriconazole (VCZ) is frequently utilized for prevention and treatment of invasive fungal infections in peripheral stem cell transplant (PSCT) patients. We performed an open-label pharmacokinetic study to compare VCZ and N-oxide voriconazole (N-oxide VCZ) pharmacokinetics in patients pre- and post-PSCT. Ten patients completed both sampling periods. The pharmacokinetics of VCZ were unchanged; however, those of N-oxide VCZ were significantly different pre- and post-PSCT.